← ANI PHARMACEUTICALS INC ANIP
Market Price
$76.52
Market Cap
$1.70B
P/E Ratio
23.05
Revenue (FY 2025)
↑43.8% YoY
$883.37M
3-Yr CAGR: 40.8%
Net Income
↑522.9% YoY
$78.34M
Net Margin: 8.9%
Free Cash Flow
↑258.7% YoY
$171.39M
FCF Yield: 10.08%
EPS (Diluted)
↑419.2% YoY
$3.32
Basic: $3.50
Return on Equity
Efficiency
14.5%
ROA: 10.4%
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (ANIP)
All monetary values in millions ($M)| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2016 | $128.6M | — | $79.8M | $3.9M | — | $0.34 | — | $27.5M | $22.9M | — |
| FY 2017 | $176.8M | +37.5% | $97.8M | $-1.1M | -127.4% | $-0.09 | -126.5% | $39.4M | $29.1M | +26.8% |
| FY 2018 | $201.6M | +14.0% | $128.6M | $15.5M | +1,540.0% | $1.30 | +1,544.4% | $67.1M | $61.3M | +111.1% |
| FY 2019 | $206.5M | +2.5% | $143.4M | $6.1M | -60.7% | $0.50 | -61.5% | $45.6M | $39.0M | -36.4% |
| FY 2020 | $208.5M | +0.9% | $121.3M | $-22.5M | -470.0% | $-1.88 | -476.0% | $15.3M | $9.1M | -76.6% |
| FY 2021 | $216.1M | +3.7% | $115.5M | $-42.6M | -88.9% | $-3.40 | -80.9% | $3.3M | $0.8M | -91.6% |
| FY 2022 | $316.4M | +46.4% | $177.6M | $-47.9M | -12.4% | $-3.05 | +10.3% | $-31.2M | $-40.1M | -5,339.1% |
| FY 2023 | $486.8M | +53.9% | $305.3M | $18.8M | +139.2% | $0.85 | +127.9% | $119.0M | $110.1M | +374.7% |
| FY 2024 | $614.4M | +26.2% | $364.2M | $-18.5M | -198.6% | $-1.04 | -222.4% | $64.0M | $47.8M | -56.6% |
| FY 2025 | $883.4M | +43.8% | $542.1M | $78.3M | +522.9% | $3.32 | +419.2% | $185.2M | $171.4M | +258.7% |
Valuation
Market Price
$76.52
Market Cap
$1.70B
Enterprise Value
$1.72B
P/E Ratio
23.05
P/B Ratio
3.22
FCF Yield
10.08%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
61.36%
Operating Margin
12.58%
Net Margin
8.87%
Return on Equity (ROE)
14.49%
Return on Assets (ROA)
10.40%
Asset Turnover
1.17x
Revenue 3-Yr CAGR
40.81%
Financial Health & Liquidity
Current Ratio
44.82
Cash Ratio
17.00
Debt / Equity
0.572
Debt / Assets
0.410
Cash & Equivalents
$285.58M
Total Debt
$309.11M
Book Value / Share
$23.78
Cash Flow Efficiency
Operating Cash Flow
$185.22M
Capital Expenditures (CapEx)
$13.84M
Free Cash Flow
$171.39M
OCF / Revenue
20.97%
FCF / Revenue
19.40%
FCF 3-Yr CAGR
N/A
Per Share Metrics
EPS (Diluted)
$3.32
EPS (Basic)
$3.50
Dividends / Share
N/A
Book Value / Share
$23.78
EPS YoY Growth
419.23%
Balance Sheet (FY 2025)
Total Assets
$753.12M
Total Liabilities
$16.80M
Stockholders' Equity
$540.72M
Current Assets
$753.12M
Current Liabilities
$16.80M